Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Oral Board Mastery > Renal Cancer > Flashcards

Renal Cancer Flashcards

1
Q

What percentage of surgically resected tumors < 4 cm are benign?

A

15-20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What percentage of RCC cases are familial? What are syndromes?

A

4-6%

Von Hippel-Lindau (VHL)

Birt Hogg-Dube (BHD)

Hereditary leiomyomatosis RCC (HLRCC)

Succinate dehydrogenase deficiency

Tuberous sclerosis

BAP-1

PTEN hamartoma (Cowden Syndrome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Major subtypes of RCC?

A

clear cell

papillary 1 or 2

chromophobe

collecting duct

unclassified

uncommon: acquired cystic, clear cell tubulo papillary, renal medullary (sickle cell)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Advanced PE findings?

A

Paraneoplastic syndromes (htn, polycythemia, hypercalcemia)

adenopathy

varicocele

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Name benign renal tumors?

A

Papillary adenoma

Oncocytoma

AML

Metanephric adenoma

Adult cystic nephroma

Mixed epithelial stromal tumors

Juxtaglomerular cell tumor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is T1 renal tumor? subtypes?

A

T1 → < 7 cm in greatest dimension, limited to kidney

T1a < 4 cm

T1b < 4 cm, but not > 7 cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe renal tumor T2:

A

T2 → >7 cm in greatest dimension, limited to kidney

T2a → > 7 cm but < 10 cm

T2b → > 10 cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe renal mass T3:

A

T3 → tumor extends into major veins or perinephric tissues, but not to adrenal or beyond Gerota’s

T3a → into renal vein or its segmental branches, or invades pelvicalyceal system, or invades perirenal and/or renal sinus fat but not beyond Gerota’s

T3b → Grossly extends into vena cava below diaphragm

T3c → extends into vena cava above diaphragm or invades wall of vena cava

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe renal mass T4:

A

T4 → invades beyond Gerota’s (including contiguous adrenal extension)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Define renal cancer N and M stages:

A

Nx → LN not assessed

N0 → no region LN mets

N1 → mets to regional LN

M0 → no distant mets

M1 → distant mets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe renal mass stages:

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the treatment options for clinically localized renal cancer:

A

Active surveillance → cT1a < 4 cm → risk of mets <2%

Radical Nx → historically entire kidney, Gerota’s/ Zuckerkandel’s fascia, regional LN, and adrenal

Partial Nx → NSS

Thermal ablation → RFA and cryoablation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

In a patient with renal mass, clinicians SHOULD obtain which imaging? How is mass characterized?

A

GUIDELINE STATEMENT 1

High-quality, multiphase, cross-sectional abdominal imaging (CT/MRI)

eGFR < 45 → hydration or MRI (especially characterizing small lesions < 2 cm)

NSF (CKD 4/5 → < 0.07%)

Characterize stage (size cranio-caudal, transverse, and A/P, morphology, involvement of vasculature, adenopathy)

Nephrometry score, PADUA score, C-index

Complexity (Bosniak 3 → irregular walls/septa + enhancement ~50% malignant; Bosniak 4 → complex cystic lesions, enhancing ~75-90% malginant)

Degree of contrast enhancement (> 15-20 HU on CT or 20% on MRI)

Presence or absence of fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nephrometry Score

A

RENAL

Radius, Exophytic/Endophyic, Nearness to CS, A/P, Location re: polar lines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

In patients with suspected renal cancer, clinician SHOULD obtain which labs? Metastatic eval?

A

GUIDELINE STATEMENT 2

CMP, CBC, UA (proteinuria important prognostic factor)

UA 1+ protein → Protein: Cr or Alb:Cr

Elevated ALP → consider bone mets

Chest imaging → CXR or CT(evaluate for thoracic mets based on risk of dz)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What makes a renal mass higher risk?

A

presence of thrombi, presumed adenopathy, larger tumor size, infiltrative appearance, extensive tumor necrosis, severe relevant sxs or PE findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

In patient with solid or Bosniak 3 or 4 mass, in addition to labs and metastatic workup, what other classifications SHOULD be done?

A

GUIDELINE STATEMENT 3

Assign CKD stage base on GFR and degree proteinuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

In regards to counseling for suspicious renal mass, who SHOULD be considered as players of the multidisciplinary team?

A

GUIDELINE STATEMENT 4

Urologist → lead counseling process

IR → RMB or ablation

Nephrologist → CKD, proteinuria, DMII, ongoing renal protection

Pathologist → GU dedicated, also evaluation of normal parenchyma

Medical Oncologist → poss neoadjuvant or adjuvant trials, recurrence

Genetic Counseling → 4-6% familial, multifocal or b/l

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Clinicians SHOULD provide counseling that includes current perspectives about tumor biology and what patient-specific risk assessment:

A

GUIDELINE STATEMENT 5

Sex, tumor size/complexicty, histology, imaging characteristics

cT1a (low oncologic risk → indolent, <2% risk mets)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

When counseling treatment options for renal mass, clinicians SHOULD review the most common urologic and non-urologic morbidities of each treatment pathway including:

A

GUIDELINE STATEMENT 6

the importance of age, comorbidities/frailty, and life expectancy

RN → greatest risk dec. GFR or de novo CKD, favorable peri-op outcomes and low risk of complication compared to PN

PN → excellent preservation of GFR, higher risk txf, urine leak or other complications needing additional tx (stent, drains, embolization of pseudo-aneurysm)

TA → inferior RFS, most favorable peri-operative outcome profile (best for small peripheral tumors)

AS → favorable oncologic and OS outcomes in well-selected patients; possible anxiety or poor outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What SHOULD clinicians review in regards to renal function recovery related to renal mass management:

A

GUIDELINE STATEMENT 7

Progressive CKD

ST and LT need for RRT

LT OS considerations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Clinicians SHOULD refer to nephrology renal mass patients with:

A

GUIDELINE STATEMENT 8

High risk of CKD progression (eGFR < 45), confirmed proteinuria, DMII pre-existing CKD, or expected GFR < 30 after sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

In regards to renal cancer, when is genetic counseling RECOMMENDED:

A

GUIDELINE STATEMENT 9

< 46 yo

Multifocal or b/l masses

personal hx suggests familial renal neoplastic syndrome

1st or 2nd degree relative with hx of renal cancer or known clinical/genetic dx of familial neoplastic syndrome (even if kidney cancer not observed)

path demonstrates histologic features suggestive of syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Syndrome: Von Hippel-Lindau (VHL)

A

Gene: VHL

Clear cell RCC, renal cysts, hemangioblastomas of CNS, retinal angiomas, pheochromocytoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Syndrome: Hereditary Papillary Renal Carcinoma (HRPC)
Gene: MET Type 1 papillary RCC
26
Syndrome: Birt Hogg-Dube (BHD)
Gene: FLCN chromophobe RCC, oncocytoma, hybrid oncocytic/chromophobe tumors (HOCTs), cc RCC (less common), renal cysts, cutaneous fibrofolliculomas, lung cysts, spontaneous PTX
27
Syndrome: Hereditary Leiomyomatosis and RCC (FH)
Gene: FH type 2 papillary or CD RCC, cutaneous leioyomyomas, uterine leiyomyomas
28
Syndrome: Succinate Dehydrogenase Kidney Cancer (SDH-RCC)
Gene: SDHB/C/D ccRCC, choromophobe RCC, type 2 papillary RCC, oncocytoma, pheochromocytoma/paraganglioma
29
Syndrome: BAP-1 Tumor Predisposition Syndrome
Gene: BAP-1 ccRCC, uveal melanoma
30
Syndrome: Tuberous Sclerosis Complex
Gene: TSC 1 or 2 AML, ccRCC, oncocytoma, lymphangioleiyomyomastosis (LAM), seizures, developmental delay
31
Syndrome: Cowden/PTEN Syndrome associated RCC (CS-RCC)
Gene: PTEN Thyroid, breast, and endometrial cancer, mucocutaneous lesions, RCC with papillary mc, other forms of RCC including cc
32
When considering RMB what SHOULD be counseled?
GUIDELINE STATEMENT 10 generally safe & complications low risk: hematoma, pain, hematuria, PTX, hemorrhage (txf) Sensitivity 9.67%, Specificity 94.4%, PPV 98.8% (core), NPV 60-80% non-diagnostic rate 14%, concern for missed histologic heterogeneity Discussion: RMB is safe and low risk (no reported tumor seeding) Dx of RCC is highly reliable LImits: Benign bx must be distinguished from non-dx Benign is not always correct Grade concordance from bx to sx is not perfect Oncocytic neoplasm are diagnostic dilemma Bx or aspiration of cystic mass not advised (spillage)
33
When concerned about hematologic, metastatic, inflammatory, or infectious mass, clinicians SHOULD consider? What type of cancers are common?
GUIDELINE STATMENT 11 RMB Lymphoma, lung, melanoma, colon, thyroid
34
RMB SHOULD be obtained on utility-based approach when it may influence mgmt. It is NOT required when:
GUIDELINE STATMENT 12 Young or healthy patients who are unwilling to accept uncertainties older or frail patients who will be managed conservatively no matter results
35
How SHOULD RMB be done?
GUIDELINE STATEMENT 13 Multiple core biopsies and preferred over FNA
36
Why is NSS (PNx) important? When is it appropriate to consider?
GUIDELINE STATEMENT 14 for mgmt of cT1a mass \*\*reduces risk of CKD or CKD progression and is associated with favorable outcomes GUIDELINE STATEMENT 15 solid or Bosniak 3 or 4 complex cystic masses in anatomically or functional solitary kidney, bilateral tumors, known familial RCC, pre-existing CKD, or proteinuria GUIDELINE STATEMENT 16 solid or Bosniak 3 or 4 complex cystic masses who are young, multifocal masses, or comorbidities likely to impact GFR in future (htn, DM, stones, obesity)
37
Intraoperatively, how SHOULD clinicians prioritize nephron sparing and balance with what other goals?
GUIDELINE STATEMENT 17 optimize nephron mass preservation avoid prolonged warm ischemia (\<25-30 mins) GUIDELINE STATEMENT 18 Prioritize negative sx margins Enucleation should be considered in pts with familial RCC, multifocal dz, severe CKD \*depends on tumor characteristics, growth pattern, interface with normal tissue
38
When SHOULD a clinician consider RNx?
GUIDELINE STATEMENT 19 Solid or Bosniak 3 or 4 complex cystic renal mass with: increased oncologic potential (size, RMB, imaging features) ALL of following: high tumor complexity (PN challenging in experienced hands) no pre-existing CKD or proteinuria normal contralateral kidney (new baseline GFR would be \>45)
39
Patients undergoing renal sx, SHOULD have LND when?
GUIDELINE STATEMENT 20 clnically concerning regional LAN, perform LND including all clinically positive nodes for staging (no real survival benefit) (concerning features: \> 10 cm mass, clinical stage T¾, high grade tumors (3 or 4), sarcomatoid features, histologic tumor necrosis)
40
For patients with renal mass, when SHOULD adrenalectomy be performed?
GUIDELINE STATEMENT 21 imaging and/or intraoperative findings suggest mets or direct invasion of adrenal gland pT4 (contiguous) M+ if hematogenous
41
How SHOULD renal mass surgery be performed?
GUIDELINE STATEMENT 22 Minimally invasive (when it would not compromise outcomes) \*benefits in ST complications, fewer longer term
42
After PNx of RNx, adjacent renal parenchyma SHOULD be evaluated:
GUIDELINE STATEMENT 23 evaluate for intrinsic renal dz and particularly for CKD or risk factors for CKD
43
When SHOULD clinicians refer to medical oncology for renal masses?
GUIDELINE STATEMENT 24 whenever there is concern for potential clinical mets or incompletely resected dz (macroscopic positive margin or gross residual dz) patients with high-risk or locally advanced, fully resected renal cancers should be counseled of risk, benefits of adjuvant tx and encourage to participate in trials
44
What types of TA can be considered for renal mass? Who SHOULD be considered?
GUIDELINE STATEMENT 26 radiofrequency ablation (RFA) and cryoablation GUIDELINE STATEMENT 25 consider as alternative mgmt of cT1a solid masses \< 3 cm (percutaneous preferred over sx approach)
45
Describe RFA and cyroablation:
RFA → high frequency alternative current (460-500 kHz) to induce frictional agitation and heating in adjacent tissues Cryo → temp -20 to -40 C, resulting in coagulative necrosis
46
When treating with TA, what SHOULD be performed prior to or at time of tx? What should counseling include?
GUIDELINE STATEMENT 27 RMB to provide pathologic dx and guide surveillance GUIDELINE STATEMENT 28 info regarding increased likelihood of persistence or local recurrence vs. sx which may be addressed with repeat ablation or further intervention
47
Patient related factors for AS vs. Expectant Mgmt vs. Intervention
48
When SHOULD AS be utilized?
GUIDELINE STATEMENT 29 For solid renal mass \< 2 cm, or complex but cystic \*Repeat imaging in 3-6 mo to assess growth/change, then periodic imaging based on growth rate GUIDELINE STATEMENT 30 For solid or Bosniak 3 or 4 cystic complex mass, WHEN anticipated risk of intervention or competing risk of death outweigh oncologic benefits (asx pts periodic imaging) GUIDELINE STATEMENT 31 For patients with solid or Bosniak 3 or 4 WHEN risk/benefit is equivocal and who prefer AS, consider RMB
49
When is intervention RECOMMENDED over AS? When is AS possible in this case?
GUIDELINE STATEMENT 32 solid or Bosniak 3 or 4 mass with oncologic benefits of intervention \> risks of tx and risk of death _\*\*Median growth rates \> 5 mm/year are indicative of oncologically active tumors_ AS with potential for delayed intervention → only if patient understands and willing to accept associated oncologic risk Encourage RMB for additional stratification continues to prefer AS → close clinical and cross sectional imaging continued
50
Follow up after intervention of renal mass: benign vs. malignant?
GUIDELINE STATEMENT 33 Discuss implications of stage, grade, and histology including risk of recurrence and sequelae of tx Benign → occasional clinical eval and labs (no imaging) GUIDELINE STATEMENT 34 Periodic H&P, labs, imaging for mets and local recurrence based on stage
51
What follow up labs for malignant renal mass s/p tx?
GUIDELINE STATEMENT 35 Cr, eGFR, UA CBC, LDH, LFT, ALP, Ca → discretion of MD or if advanced dz
52
When following patient s/p tx for renal mass, when do you refer to nephrology?
GUIDELINE STATEMENT 36 with progressive renal insufficiency or proteinuria
53
When do you perform bone scan for renal mass f/up post tx? When head or spine CT/MRI?
GUIDELINE STATEMENT 37 clinical sxs bone pain, elevated ALP, or imaging suggestive of bony mets GUIDELINE STATEMENT 38 Acute neuro sxs GUIDELINE STATEMENT 39 site specific imaging warranted by sxs PET should not be routinely used (selectively)
54
Patients renal mass with suggestive sxs/signs of mets next steps?
GUIDELINE STATEMENT 40 evaluate to define extent of dz refer to med onc sx or ablation considered with isolated or oligo-mets
55
In pts with new renal primary or local recurrence, what is next steps?
GUIDELINE STATEMENT 41 met evaluation including chest and abdomen if isolated to ipsilateral kidney and/or retroperitoneum, sx resection or ablation can be considered
56
Describe risk categories of patients s/p PNx or RNx:
GUIDELINE STATEMENT 42 See table, sx margins positive → increase risk category by one level
57
Recurrence rates by risk level for renal mass post sx:
pT1 → 9.2% (Grade 1: 6.4%, Grade 2: 15.4%) pT2 → 32% (organ confined RCC, Grade 3 or 4: 20-30%) pT4 (most present mets) → 64.7% (N1 → CSS 2.8 y, 64.3% mortality after recurrence)
58
Follow up after TA:
GUIDELINE STATEMENT 45 bx confirmed malignancy or non-dx CTU/MRU w/in 6 mo (then follow same as intermediate risk category)
59
f/up schedule after surgery for renal cancer:
GUIDELINE STATEMENT 43 and 44 Low risk → pT1, G1 or 2 → CT/MRI and CXR/CT q 12 mo \*after 2 years abd US alternating with CT/MRI can be considered \*after 5 y joint decision making Intermediate risk → pT1 grade 3 or 4, pT2 any grade → CT/MRI and CXR/CT at 6 mo, then q 12 mo for 5 years (can consider abd US after 2 years alternating) High risk → pT3 any grade → CT/MRI and CXR/CT q 6 mo for 3 y, then q 12 mo for 5 years Very high risk → pT4 or N1 or sarcomatoid, rhabdoid, macro pos margin → CT/MRI q 3 mo x 1year, then q 6 mo years 2-3, then annually
60
f/up algorithm table for renal mass
61
Describe an extraperitoneal flank approach for Nx:
1. Anesthesia, Foley, SCDs, abx 2. Position lateral decubitus (side down opposite tumor), flexion to increase space btw ribs, pressure points padded, secured to table, right arm supported in anatomic position to protect brachial plexus 3. Incise btw 11-12 ribs, dissect through flank layers, care to avoid perforating nerves 4. Enter retroperitoneum, divide lumbodorsal fascia, avoid entry to pleura posteriorly and peritoneum anteriorly 5. Mobilize kidney w/in Gerota's posteriorly, laterally, superiorly, and anteriorly 6. ID ureter 7. Place kidney on anterior and medial traction to isolate hilum 8. Dissect artery posteriorly 9. Defat kidney near renal mass, maintain fat pedicle to possibly use for reconstruction 10. Use US if needed to define boundaries and depth 11. Mannitol??? /IVF (out of favor…) 12. Clamp RA, surround kidney in slush 13. Incise capsule 1 cm from tumor edge, excise tumor with neg margin 14. Sample areas from bed if concern of incomplete excision 15. Assess and repair CS 16. Achieve hemostasis with focal suture ligatures, electrocautery, and hemostatic agents 17. Reconstruct and reinforce defect (bolsters) 18. Remove clamp ASAP 19. Assess for arterial pulse/perfusion kidney 20. Assess for hemostasis 21. Re-approximate perinephric fat pedicle 22. Place drain in proximity of kidney 23. Inspect retroperitoneum, peritoneal boundary and pleura 24. Inspect vasculature 25. Remove flexion, reapproximate ribs 26. Close muscle and facial layers 27. Close skin
62
How do you manage an acute post operative urine leak?
1. vast majority close with conservative mgmt 2. small leaks → adjust drain to make sure not contributing, suction on renorrhaphy vs. obs 3. larger or persistent leaks → urinary diversion, stent, IR drain/PCN; with stent need Foley to prevent VUR 4. Secondary closure, fistula repair, nx (challenging cases or nephrocutaneous fistula) 5. Algorithm: leak from drain → take off suction → adjust away from anastomosis Insert stent → placed PCN → IR drain urinoma → antegrade stent
63
Most important prognostic determinant of RCC?
local tumor extent/size/stage histologic subtype surgical margins regional nodal status evidence of distant met status performance status
64
What about margins?
\<1 cm margins not associated with higher rates of local recurrence positive margin slightly higher risk of local recurrence (but with adequate surveillance, no statistically higher mortality)
65
What are risk factors and pathogenesis of ccRCC? what about VHL association?
family hx, smoking, hereditary, obesity, HD arises from PCT, associated with defects in VHL (60% sporadic) VHL → works as tumor suppressor to inhibit ubiquitination of HIF → when mutated HIF builds up overproducing VEGF, GLUT-1 TGF-a, PDGF → angiogenesis, proliferation
66
Describe trans peritoneal lap Nx:
1. anesthesia, foley, NGT 2. lateral decubitus (tumor side up), 45 degree angle, pad pressure points (peroneal nerve, brachial plexus stretch injury) 3. trochar placement to triangulate kidney 4. Veress → incision at umbilical camera site → Kelly clamp to spread fat, ID fascia → grasp fascia using Kocher, upward traction, pass veress (2 pops) → 10 cc syringe, inject 5 cc saline without force to confirm intraperitoneal → advance needle 1 cm, no resistance → confirm low starting pressure → remove Veress, place trochar, attach gas, pass camera to inspect 5. Hasson → consider with prev. abd sx → ID fascia, incised, peritoneum incised → 2 heavy sutures placed on either size of incision (incorporate fascia/peritoneum) → Hasson trochar in place and insufflation started 6. Place working trochars under direct vision 7. take down colon (white line of Toldt), care not to enter Gerota's (left splenic flexure mobilized → drop from field, care to avoid tail of pancreas 8. ID ureter on psoas 9. gonadal ID and traced to hilum 10. RV skeletonized (care not to avulse adrenal vein or lumbar (entering posterior RV) 11. ID RA posterior and superior (make sure 1) 12. Secure RA with Weck Clips (2-3, 1 on kidney side) or Stapler, Take vein with stapler 13. Take gonadal and ureter, dissect free posterior, lateral, and superior aspect of kidney, place in bag 14. Extract in lap bag to facilitate removal and reduce incision site implants 15. Port sites \> 10 mm closed
67
Common locations of positioning injuries for renal sx:
Brachial plexus Lateral popliteal nerve Femoral nerve Sciatic Nerve \*usually resolve 4-6 weeks, can last up to 2y
68
What are insufflation/access related complications and treatment:
gas embolus → Millwheel murmur, CV collapse, head/neck cyanosis, dysrhythmia, hypoxia, decreased end tidal CO2 → terminate insufflation, release pneumo, left lateral decubitus, cardiopulmonary resuscitation, aspiration of gas via central line, 100% O2 Veress needle/trochar placement → major vascular injury → leave needle in place, use second Veress and try to repair injury → if trochar injury, open conversion, explore and repair → do not remove until conversion made and ID location and severity Extraperitonal insufflation → high intra-abd pressure after small volume insufflated, subq emphysema, pneumoscrotum, PTX, pneumomediastinum → reposition insufflation needle
69
Name vascular complications and tx of lap surgery:
mgmt. based on severity of injury: clip vessel, increase pressure, apply pressure (gauze or instrument), biosealants (slow ooze), oversew, convert to open/hand assist (leave instrument on bleed), lower pressure to 5 mHg at end to ensure no active bleeding (watch trochar removal) post operative bleeding → prolonged pain, distention, tachy, fall in hct → CT AP, obs. vs. exploration Hollow viscus → electrocautery, access (needle/trochar), blind passage of instruments Recognize in OR → repair, abx irrigation, broad spectrum Post op → trochar site pain, fever, leukopenia with left shift, low threshold for CT w/oral contrast and delayed views to visualize colon Solid Viscus → veress, trochar, retraction (do gently) Minor injury → biosealants, argon beam, cellulose gauze, open if fail Kidney trochar injury → if Gerota's intact, stable RP hematoma, patient stable \_\> conservative obs Explore if expanding hematoma, vascular instability, or unknown extent of injury
70
Complications of PNx:
Intraoperative hemorrhage Delayed bleeding Persistent leak from CS Perirenal abscess Urinoma Reno-cutaneous fistula Acute tubular necrosis Conversion to RN
71
what control is needed with IVC thrombectomy?
* **Prior to IVC thrombectomy vascular occlusion should include**: * **Renal artery supplying the affect kidney with tumor thrombus** * **Infrarenal IVC below thrombus** * **Lumbar veins feeding in to the IVC** * **Contralateral renal vein** * Hepatic blood supply for thrombus that extends about the hepatic veins. A **Pringle maneuver** is performed to decreased hepatic blood flow by placing a clamp across the hepatic artery and portal vein within the hepatoduodenal ligament. This is mainly done for level 3 or higher tumor thrombus. * **Suprarenal IVC above the thrombus**
72
IVC thrombus classification:
* In the eighth edition AJCC staging manual, venous invasion is classified by the T stage according to the extent of invasion as described below: * **T3a tumor grossly extends into the renal vein or its segmental (muscle containing) branches** * **T3b tumor grossly extends into the vena cava below the diaphragm** * **T3c tumor grossly extends into the vena cava above the diaphragm** * However, the **Neves Zincke** classification is more useful from a technical surgical approach:[113](https://university.auanet.org/core/oncology-adult/renal-neoplasms/index.cfm?&ct=732f2f653c1b8c46b85ee264ee17f16de174c7f79db565af72a4abdf1b3b918781d11542c0555f10607f8cc4042a0197acb826bb3f2978aa6b6572e6d708a06d#ref_9036) * **Level 0: Tumor thrombus limited to renal vein** * **Level 1: Extending ≤2 cm above the renal vein** * **Level 2: Extending \>2 cm above the renal vein but below the hepatic veins** * **Level 3: At or above the hepatic veins but below the diaphragm** * **Level 4: Extending above the diaphragm**
73
Where does RCC metastasize?
Lung → 50% Liver → 33% Bone 32 → 32 Brain → 25%
74
5 year survival for RN by stage?
Stage 1 → 95% Stage II → 85% Stage III → 60% Stage IV → 20%
75
What are s/s important to ask at renal mass f/up after Nx or PNx? PE components?
History: abdominal/flank/bladder pain or tenderness fatigue gross hematuria weight loss lower extremity edema neuro complaints MSK pain SOB PE: LN, lower extremities, neuro exam, VS (weight and BP), abdominal exam
76
Labs to consider for f/up of post sx renal mass??
CBC, LDH, LFTs, UA, BUN/Cr (eGFR), ALP (sxs)
77
What is ddx of post sx bone pain (ribs) and elevated ALP on f/up?
Hyperthyroidism Pregnancy Hepatitis Biliary Obstruction Non malignant bone conditions (Pagets) Bone mets
78
What is ddx of solid enhancing renal mass?
RCC vascular malformation infarct urothelial carcinoma oncocytoma AML metanephric adenoma Met dz renal abscess XGP
79
What are risk factors for AKI with IV contrast?
htn pre-existing CKD hemodynamic instability volume depletion Age \> 75 yo CHF High volume contrast media
80
What tactics can be utilized to prevents kidneys with IV contrast load?
adequate oral hydration IV NaCl or NaCO3 solution discontinue nephrotoxic meds stop metformin and restart in 48 h use lowest dose iso- or low osmolar IV contrast agent NAC
81
What do you look at for post-ablation CT?
additional, new renal nodules satellite or port site soft tissue nodules size change of mass (increase or decrease) enhancement
82
what are tx options for post ablation failure?
salvage RNx salvage PNx repeat bx repeat ablation
83
MC IVC injuries during PNx or Nx
avulsion of right adrenal vein from IVC or right gonadal from IVC
84
Define Bosniak classification of renal cystic tumors:
Bosniak 1: simple cyst, 0% malignancy Bosniak 2: minimally complex cyst, 0% malignancy Bosniak 2F: more minimally complex cyst, 5% malignancy Bosniak 3: indeterminate, 55% malignancy Bosniak 4: clearly malignant, 100% malignancy
85
Early Post-Op complication of PNx?
1. Delayed bleeding 1. work up pseudo-aneurysm with CT w/IV contrast → call IR for embolization 2. Urinoma 1. Place ureteral stent anf oley 2. If persists, IR drain 3. Perinephric abscess 1. evaluate for urinoma source 2. IR rain 3. if persists, consider open drainage
86
Late Post-op complications of PNx?
1. UJPO: scarring around hilum and UPJ 2. HTN, with renal trauma also 5% (page kidney) 3. AVM

Oral Board Mastery (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions